CAS 156918-66-0 | CT-2584-006 : CT-2584
(World's Largest Pharmaceutical Supplier)
- CAS Number: 156918-66-0
- Stock: 999g
- Assay: 0.00%
CAS 156918-66-0, also known as alogliptin, is a medication used in the treatment of type 2 diabetes. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones in the body, thus lowering blood sugar levels.
Alogliptin was approved for use by the United States Food and Drug Administration (FDA) in 2013, and has since become widely prescribed. It is typically taken orally once a day, either alone or in combination with other diabetes medications.
In addition to its primary use in treating diabetes, alogliptin has also been investigated for its potential use in treating other conditions. For example, some studies have suggested that it may be beneficial in reducing the risk of cardiovascular disease in patients with type 2 diabetes.
Like all medications, alogliptin can cause side effects. Some common side effects include upper respiratory tract infections, headaches, and diarrhea. In rare cases, it may also cause pancreatitis or severe joint pain.
Despite its potential side effects, alogliptin has been shown to be an effective treatment for type 2 diabetes, helping to improve blood sugar control and reduce the risk of complications associated with the disease. As such, it is a valuable tool in the management of this chronic condition, and continues to be an important area of research and development in the field of diabetes care.